Search results
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
Zacks· 6 days agoFree Report) boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor Keytruda approved for several types of cancer and alone accounting ...
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
Barrons.com· 2 days agoThe American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual...
AstraZeneca’s $80B sales plan leans on cancer drug expansion
BioPharma Dive via Yahoo Finance· 5 days agoOne of the drugs, the lung cancer treatment Tagrisso, has already exceeded $5 billion in annual...
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Benzinga via Yahoo Finance· 2 days agoKeytruda (pembrolizumab) is Merck & Co Inc’s (NYSE:MRK) top selling cancer drug. The abstract...
ASCO24: An early look at cancer drug study results
BioPharma Dive via Yahoo Finance· 3 days agoClinical trial abstracts posted Thursday ahead of this year’s ASCO meeting give a peek at anticipated datasets from Immunocore, Merus, J&J and Merck &...
Immunotherapy for stomach cancer: Types and effectiveness
Medical News Today· 3 days agoImmunotherapy may help shrink a tumor or slow the growth of cancer cells. People may have it in...
Why This Top 4% Biotech Just Catapulted To A Record High
Investor's Business Daily· 2 days agoThe Netherlands-based biotech paired its drug, petosemtamab, with Merck's (MRK) cancer blockbuster, ...
Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
Zacks· 2 days agoFree Report) announced updated clinical results from a cohort of the phase II IOV-COM-202 study evaluating the combination of its recently approved cell therapy Amtagvi and Merck’s blockbuster ...
ASCO: Early peek at Merus' bispecific cancer data lives up to investors' expectations
FierceBiotech· 2 days agoAnalysts have hailed Merus’ latest data drop in head and neck cancer as meeting investors’...
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
FOX 23 News Albany· 3 days agoEisai announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology ...